These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32236158)
41. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
42. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? Ramamurthy C; Godwin JL; Borghaei H Curr Treat Options Oncol; 2017 Jun; 18(6):33. PubMed ID: 28534248 [TBL] [Abstract][Full Text] [Related]
43. Personalised cancer management: closer, but not here yet. Piccart M Ann Oncol; 2013 Aug; 24(8):1951-5. PubMed ID: 23878113 [No Abstract] [Full Text] [Related]
45. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Formisano L; Jansen VM; Marciano R; Bianco R Anticancer Agents Med Chem; 2018; 18(9):1235-1240. PubMed ID: 28901258 [TBL] [Abstract][Full Text] [Related]
46. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Hsu PC; Jablons DM; Yang CT; You L Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256 [TBL] [Abstract][Full Text] [Related]